Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up,…

What with long summer days and vacations, it can be tough to keep up with required reading in July. To catch up with the best-read news, check out FiercePharma…

The Justice Department has drawn Celgene into its pharma-wide probe of financial ties with patient assistance programs, which help cover out-of-pocket drug…

As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…

The FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black box. The drugs'…

Pharma, already smarting in Japan from new price controls imposed by the government, may now face additional limits on new breakthrough drugs. Up first for…

Back when it was fending off Pfizer’s hostile takeover attempt, AstraZeneca found support from some officials in the U.K. who blasted the deal on its potential…